Study wrapper · #1149
Composition and Labelling Accuracy of Products Sold as Retatrutide in Australia.
Piatkowski T, Craven A, Cornell S, et al. Drug and alcohol review. 2026.
DOI: 10.1111/dar.70231PubMed: 42559975
Editor's note
Retatrutide is not approved anywhere, which means every vial sold under that name comes from the grey market — and independent testing of what those vials contain is exactly the kind of evidence this beat lacks. This team has previously documented mislabeled and inaccurately dosed peptide products in Australia's unregulated supply. The abstract is not yet available, so we are noting the paper now and will report the composition findings once we can review the full text.
Plain-language abstract
Australian researchers analyzed what is actually inside products sold as retatrutide — a drug still in clinical trials with no approved commercial version — checking whether contents match the labels.
Related coverage
Mixed
Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Journal of chromatography. An=——2026
Supported
Comparative effects of semaglutide tirzepatide and retatrutide on renal fibrosis in UUO and aged mice.
iSciencen=——2026
Supported
CARDIOVASCULAR EFFECTS OF INCRETIN RECEPTOR AGONISTS: BEYOND GLYCEMIC CONTROL.
Canadian journal of physiology and pharmacologyn=——2026